These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 14734481)

  • 1. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
    Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
    Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
    Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
    Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
    J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
    Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
    Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer.
    Machitani M; Sakurai F; Wakabayashi K; Tachibana M; Fujiwara T; Mizuguchi H
    Mol Cancer Ther; 2017 Jan; 16(1):251-259. PubMed ID: 27760834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus.
    Hashimoto Y; Watanabe Y; Shirakiya Y; Uno F; Kagawa S; Kawamura H; Nagai K; Tanaka N; Kumon H; Urata Y; Fujiwara T
    Cancer Sci; 2008 Feb; 99(2):385-90. PubMed ID: 18201270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
    Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Tanaka N
    Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.
    Gürlevik E; Woller N; Strüver N; Schache P; Kloos A; Manns MP; Zender L; Kühnel F; Kubicka S
    Mol Ther; 2010 Nov; 18(11):1972-82. PubMed ID: 20700112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
    Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
    Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.